Quinidine therapy in Brugada Syndrome
Investigating non-invasive markers to determine the effect of quinidine treatment in patients with Brugada Syndrome.
Sydney Local Health District
15 participants
Oct 5, 2020
Interventional
Conditions
Summary
Quinidine is the only drug shown to reduce the risk of dangerous irregular heart rhythms in Brugada Syndrome. While studies have shown invasive electrophysiology studies can be useful in assessing response to quinidine in Brugada Syndrome, currently, there is no definitive way to monitor drug effect in an individual. The QUIET BrS Study will investigate the effect of quinidine on a variety of clinical parameters in patients with Brugada syndrome. We seek to identify non-invasive markers of quinidine effect in patients with Brugada Syndrome which could be used to develop a non-invasive strategy for monitoring medical therapy in these patients and reduce the need for invasive procedures.
Eligibility
Inclusion Criteria1
- Diagnosis of Brugada Syndrome
Exclusion Criteria6
- Current treatment with drug known to prolong QT interval
- Baseline QTc >450msec for men, > 460msec for women
- Baseline QRS > 130msec
- Baseline PR >200msec
- Patients taking medications known to interact with quinidine
- Known hypersensitivity to quinidine
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Hydroquinidine 300mg, oral capsule, twice daily For 2 weeks Adherence will be monitored by patient report and tablet return. Serum quinidine levels will also be performed. This is a non-randomised trial.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12620000934943